Evaluation of Anticancer Potential of Hamamelitannin in Targeting Lung Cancer Cell Proliferation and Metastasis

Abstract

This study investigates the anti-lung cancer potential of hamamelitannin through an integrated network pharmacology and experimental validation approach. Network analysis identified 28 common targets between hamamelitannin and lung cancer, with protein-protein interaction (PPI) network analysis revealing key hub targets (GASRP, CASRP, RRIX2, PGU1H) involved in highly interconnected signaling pathways. Gene Ontology (GO) and KEGG enrichment analysis indicated significant involvement in critical biological processes, particularly folate metabolism and apoptosis. Experimentally, hamamelitannin demonstrated potent, concentration dependent cytotoxicity against A549 lung cancer cells. Mechanistic studies revealed that hamamelitannin treatment significantly downregulated cyclin D1 while upregulating p21 and p27, indicating induction of G1/S cell cycle arrest. These findings suggest that hamamelitannin exerts its anti-cancer effects through multi target modulation of cell cycle regulation and metabolic pathways, positioning it as a promising therapeutic candidate for lung cancer treatment. The study provides a foundational basis for further exploration of hamamelitannin as a potential anti neoplastic agent.